Penumbra could generate healthy sales and earnings growth, gaining market share in MT. MT’s share would rise to around 50% in DVT and about 60% in PE. Don’t miss this list of 3 high-yield ...
Penumbra, Inc. (NYSE:PEN) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds. The company announced the completion of enrollment in STORM-PE clinical trial. The pivotal, ...
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% ...
Penumbra's stock has sold off sharply over the last year as decelerating revenue growth has spooked growth investors out of this high-multiple stock. Q2 results included 14% revenue growth, a small ...
Zacks.com on MSN
Reasons to Retain Penumbra Stock in Your Portfolio for Now
Penumbra, Inc.’s PEN robust product portfolio expansion is poised to drive growth in the upcoming quarters. Additionally, the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min At Penumbra Inc. Shruthi Narayan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback